Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
November 2016
-
Press Release
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
Priority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also… -
Press Release
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
Cosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high… -
Press Release
Novartis improves ranking in 2016 Access to Medicine Index
Novartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income… -
Press Release
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…
October 2016
-
Press Release
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
Basel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "… -
Press Release
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301… -
Press Release
Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster
Dank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +… -
Press Release
Novartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentiels
Chiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa… -
Press Release
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle… -
Press Release
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in… -
Press Release
Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year… -
Press Release
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…